Toll-like receptor 4 genetic variation and advanced prostate cancer risk

被引:77
|
作者
Cheng, Iona
Plummer, Sarah J.
Casey, Graham
Witte, John S. [1 ]
机构
[1] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Ctr Human Genet, San Francisco, CA 94143 USA
[3] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA
关键词
D O I
10.1158/1055-9965.EPI-06-0429
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Toll-like receptor 4 (TLR4) is a key innate immunity receptor that initiates an inflammatory response primarily against Gram-negative bacteria. Two recent publications reported that variants in TLR4 were associated with risk of prostate cancer. To further investigate the role of TLR4 in prostate cancer susceptibility, we identified six tagging single-nucleotide polymorphisms that comprehensively captured the common genetic variation of the locus and tested these polymorphisms in our case-control study of 1,012 men. Two single-nucleotide polymorphisms showed nominally statistically significant associations with prostate cancer risk, with the strongest (rs10759932) associated with a 4-fold increased risk of disease (P = 0.006). We estimated through permutation analysis that a similarly strong result would occur by chance 2.5% of the time. Our findings support previous studies and suggest that inherited differences in TLR4 influence prostate cancer risk.
引用
收藏
页码:352 / 355
页数:4
相关论文
共 50 条
  • [21] A functional Toll-like receptor 4 polymorphism increases the risk of gastric cancer
    Hold, GL
    Smith, MG
    Chow, WH
    Rabkin, CS
    Fraumeni, JF
    El-Omar, EM
    GASTROENTEROLOGY, 2004, 126 (04) : A531 - A532
  • [22] Genetic polymorphisms of an innate immune gene, Toll-Like Receptor 4, and aggressive prostate cancer risk: A systematic review and meta-analysis
    Huang, Yi-Ling
    Page, John H.
    Chen, Jen-Hau
    Lin, Yen-Ling
    Xu, Jianfeng
    Koutros, Stella
    Berndt, Sonja
    Chanock, Stephen J.
    Witte, John S.
    Chen, Yen-Ching
    CANCER RESEARCH, 2011, 71
  • [23] Toll-like receptors and prostate cancer
    Zhao, Shu
    Zhang, Yifan
    Zhang, Qingyuan
    Wang, Fen
    Zhang, Dekai
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [24] Toll-like receptor 2 and toll-like receptor 4 expression in human adrenals
    Bornstein, SR
    Schumann, RR
    Rettori, V
    McCann, SM
    Zacharowski, K
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (07) : 470 - 473
  • [25] Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer
    Chen, Yen Ching
    Huang, Yi Ling
    Platz, Elizabeth A.
    Alderete, John F.
    Zheng, Lu
    Rider, Jennifer R.
    Kraft, Peter
    Giovannucci, Edward
    Sutcliffe, Siobhan
    CANCER CAUSES & CONTROL, 2013, 24 (01) : 175 - 180
  • [26] Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality
    Stark, Jennifer R.
    Wiklund, Fredrik
    Gronberg, Henrik
    Schumacher, Fredrick
    Sinnott, Jennifer A.
    Stampfer, Meir J.
    Mucci, Lorelei A.
    Kraft, Peter
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (06) : 1859 - 1863
  • [27] Polymorphisms in Toll-like Receptor Genes - Implications for Prostate Cancer Development
    Vidas, Zeljko
    COLLEGIUM ANTROPOLOGICUM, 2010, 34 (02) : 779 - 783
  • [28] Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer
    Yen Ching Chen
    Yi Ling Huang
    Elizabeth A. Platz
    John F. Alderete
    Lu Zheng
    Jennifer R. Rider
    Peter Kraft
    Edward Giovannucci
    Siobhan Sutcliffe
    Cancer Causes & Control, 2013, 24 : 175 - 180
  • [29] SUPPRESSION OF PROSTATE CANCER GROWTH WITH ACTIVATION OF TOLL-LIKE RECEPTOR 3
    Chin, Arnold I.
    Miyahara, Andrea
    Covarrubias, Anthony
    Dempsey, Paul W.
    Cheng, Genhong
    JOURNAL OF UROLOGY, 2009, 181 (04): : 186 - 186
  • [30] The correlation of vimentin3 and toll-like receptor 4 in prostate cancer cell lines
    von Brandenstein, Melanie
    Koeditz, Barbara
    Weiten, Richard
    Storz, Enno
    Heidenreich, Axel
    CLINICAL SCIENCE, 2024, 138